Prostate Cancer - Results from #260

SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort September 13, 2024

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. September 13, 2024

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. September 13, 2024

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance. September 13, 2024

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. September 13, 2024

Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort. September 13, 2024

Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy. September 13, 2024

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. September 13, 2024

YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. September 13, 2024

PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. September 13, 2024

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. September 13, 2024

Safety and feasibility of "three arms settings" robot-assisted radical prostatectomy using the Hugo RAS system: surgical set-up in a double-center large case series. September 12, 2024

Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study. September 12, 2024

Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer. September 12, 2024

Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study. September 12, 2024

Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization. September 12, 2024

Study Confirms AI Outperforms Conventional Methods for Prostate Cancer Extracapsular Extension Detection, Offering More Accurate Risk Assessments for Surgical Decisions September 11, 2024

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm September 11, 2024

Testosterone recovery after androgen deprivation therapy. September 11, 2024

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial. September 11, 2024

Page 14 of 1435